ICP-192

Phase 2Small molecule

BBeijing InnoCare Pharma Tech Co., Ltd.

ICP-192 is one of 42 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholangiocarcinomaActive, not recruiting

Intrahepatic CholangiocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

88 competitors in Intrahepatic Cholangiocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

11 2

Beyfortus

BeiGene

Phase 2

3 3

Fudr

Pfizer

Phase 2

2 4

Pemazyre

Incyte

Phase 2

2 5

Opdivo

Bristol-Myers Squibb

Phase 2

1 6

Keytruda

Merck & Co.

Phase 2

1 7

Rocaltrol

Alnylam Pharmaceuticals

Phase 2

1 8

Stivarga

Bayer

Phase 2

1 9

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 10

Camptosar

Pfizer

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Intrahepatic Cholangiocarcinoma

NCT05678270

Clinical

Trials by Indication[1]

Bladder Urothelial Cancer1 trial

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Unknown status·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT04492293·115 enrolled

Patients With Advanced Solid Tumors1 trial

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Unknown status·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT05372120·200 enrolled

Solid Tumors1 trial

Clinical Study of ICP-192 in Solid Tumors Patients

Unknown status·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 1/2·NCT03758664·56 enrolled

Intrahepatic Cholangiocarcinoma1 trial

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT05678270·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ICP-192. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ICP-192 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ICP-192. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing InnoCare Pharma Tech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBeijing InnoCare Pharma Tech Co., Ltd.

ICP-192

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Bladder Urothelial Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Solid Tumors1 trial

Intrahepatic Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News